share_log

亞盛醫藥-B:自願公告 - 奧雷巴替尼正式獲中國國家藥品監督管理局批准,用於治療對一代和二代TKI耐藥和/或不耐受的CML-CP患者

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - OLVEREMBATINIB APPROVED BY NMPA FOR TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT

香港交易所 ·  Nov 17, 2023 07:12
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more